The limited durability of responses to anti-PD-1/PD-L1 immunotherapies in many lung cancer patients underscores the importance of identifying tumor cell-intrinsic and tumor microenvironment resistance mechanisms. This evidence concerns the gene CD274 and lung carcinoma.